NZ751995B2 - Modified factor h binding protein - Google Patents
Modified factor h binding protein Download PDFInfo
- Publication number
- NZ751995B2 NZ751995B2 NZ751995A NZ75199517A NZ751995B2 NZ 751995 B2 NZ751995 B2 NZ 751995B2 NZ 751995 A NZ751995 A NZ 751995A NZ 75199517 A NZ75199517 A NZ 75199517A NZ 751995 B2 NZ751995 B2 NZ 751995B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- modified
- fhbp
- binding protein
- nucleic acid
- composition
- Prior art date
Links
- 101710186862 Factor H binding protein Proteins 0.000 title claims abstract 28
- 239000000203 mixture Substances 0.000 claims abstract 13
- 108020004707 nucleic acids Proteins 0.000 claims abstract 9
- 102000039446 nucleic acids Human genes 0.000 claims abstract 9
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 9
- 230000002265 prevention Effects 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108010060123 Conjugate Vaccines Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229940031670 conjugate vaccine Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 206010018612 Gonorrhoea Diseases 0.000 claims 1
- 208000034762 Meningococcal Infections Diseases 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000001786 gonorrhea Diseases 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229940031937 polysaccharide vaccine Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
Abstract
The invention relates to a modified factor H binding protein (fHbp), comprising fHbp, or a variant thereof, modified with the addition of at least one exogenous peptide loop; and associated nucleic acid, compositions, and uses. The invention further relates to treatment or prevention of a pathogenic infection or colonisation of a subject using the modified factor H binding protein (fHbp).
Claims (19)
1. A modified factor H binding protein (fHbp), sing wild-type fHbp or the ype ccal homologue of fHbp (Ghfp), or a t thereof 5 having at least 75% ty with any of the sequences of SEQ ID NOs: 1-13, which is further modified with the addition of any one of PorA loops comprising a sequence according to any one of SEQ ID NOs: 45 to 79, or variant thereof having no more than 1, 2, 3, 4 or 5 amino acid additions, deletions or substitutions, 10 n the PorA loop is between 8 and 20 amino acids in length and wherein the PorA loop is inserted at an amino acid position that is corresponding to any one of the amino acid residue numbers 49-54, 83-88, 114- 124, 199-206, 227-233, and 240-246 of SEQ ID NO: 1, or equivalent residues in any one of SEQ ID NOs: 2 to 13.
2. T he ed factor H binding protein ing to claim 1, wherein the PorA loop(s) are about 16 amino acids in length.
3. The modified factor H binding protein according to any preceding claim, 20 wherein the modified fHbp comprises two or more PorA loops.
4. T he modified factor H binding protein according to any preceding claim, wherein the modified fHbp comprises between 1 and 7 PorA loops. 25
5. T he modified factor H binding protein according to any preceding claim, wherein the modified fHbp, or variant thereof, is modified with a PorA loop in at least two positions.
6. T he modified factor H binding protein according to any preceding claim, 30 wherein the modified fHbp is a fusion protein.
7. An isolated nucleic acid encoding the modified fHbp according to any one of claims 1 to 6.
8. The nucleic acid ing to claim 7, wherein the nucleic acid is a vector.
9. The nucleic acid according to claim 8, wherein the vector is a viral vector.
10. A composition sing the modified fHbp according to any one of claims 1 to 6, or the nucleic acid according to any one of claims 7 to 9.
11. The composition according to claim 10, wherein the ition comprises two or more different modified fHbp molecules.
12. The composition accor ding to claim 10 or claim 11, wherein the 15 composition comprises a pharmaceutically able carrier.
13. The composition according to any one of claims 10 to 12, wherein the composition further comprises an adjuvant. 20
14. The composition according to any one of claims 10 to 13, wherein the composition r comprises at least one other prophylactically or therapeutically active molecule.
15. The composition according to claim 14, 25 wherein the at least one other prophylactically or therapeutically active molecule comprises: a protein:capsule polysaccharide e; or a conjugate vaccine, wherein antigen(s) comprising the ed fHbp is incorporated as the protein carrier molecule in the conjugate vaccine.
16. Use of a modified fHbp according to any one of claims 1 to 6, a nucleic acid according to any one of claims 7 to 9, or a composition according to any one of claims 10 to 15, in the manufacture of a ment for treatment or prevention of a Neisseria meningitidis or Neisseria gonorrhoeae infection or colonisation of a subject. 5
17. Use of a modified fHbp according to any one of claims 1 to 6, a nucleic acid ing to any one of claims 7 to 9, or a composition according to any one of claims 10 to 15, in the manufacture of a ment for vaccination of a subject. 10
18. A c ombination of a therapeutically effective amount of the modified fHbp according to any one of claims 1 to 6, a nucleic acid according to any one of claims 7 to 9, or a composition according to any one of claims 10 to 15, and a eutically amount of a protein:capsule polysaccharide vaccine. 15
19. Use of the modified factor H binding protein (fHbp) according to any one of claims 1 to 6 as an epitope display scaffold. 3 mam SEE m@588 $ng 3E \i EEBAV ..... :x .. HT . Tantm?ummomzoogs . mmcm?ummzom @338 L330 mcEgEmE zmg?ma gEmmao?u acmEEmE SUBSTITUTE SHEET (RULE 26) E Em 0 2 LOMUML @ m mEmEoQ E“ m\\\\\\\\
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614687.0A GB201614687D0 (en) | 2016-08-31 | 2016-08-31 | fHbp scaffold |
| PCT/GB2017/052535 WO2018042178A1 (en) | 2016-08-31 | 2017-08-31 | Modified factor h binding protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ751995A NZ751995A (en) | 2024-03-22 |
| NZ751995B2 true NZ751995B2 (en) | 2024-06-25 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7094103B2 (en) | Influenza virus vaccine and its use | |
| JP6735269B2 (en) | Influenza virus vaccine and its use | |
| JP2010512792A5 (en) | ||
| JP2010099084A (en) | Fusion protein of hiv regulatory/accessory protein | |
| JP7494115B2 (en) | Modified clostridial neurotoxins as vaccine and conjugate vaccine platforms | |
| JP2009544333A5 (en) | ||
| JP2019526261A5 (en) | ||
| CN104981541A (en) | Modified coiled coil type proteins having improved properties | |
| JP2023531242A5 (en) | ||
| US12454554B2 (en) | Influenza virus vaccines and uses thereof | |
| KR20160088323A (en) | Proline-rich peptides protective against S. pneumoniae | |
| JP2019522626A5 (en) | ||
| JP2013520487A5 (en) | ||
| CN107847575A (en) | Vaccine composition for porcine reproductive and respiratory syndrome and porcine circovirus related diseases | |
| JP2020509770A5 (en) | ||
| JP2018505135A5 (en) | ||
| US12577279B2 (en) | Influenza virus vaccines and uses thereof | |
| NZ751995B2 (en) | Modified factor h binding protein | |
| IL260321A (en) | Cancer vaccines | |
| NZ751995A (en) | Modified factor h binding protein | |
| US12344635B2 (en) | COVID-19 vaccine | |
| CN106459157A (en) | Vaccines based on hepatitis b core antigens | |
| Mallajosyula et al. | In vitro and in vivo characterization of designed immunogens derived from the CD‐helix of the stem of influenza hemagglutinin | |
| CN107624117A (en) | Vaccine based on hepatitis B core antigen | |
| AU2007249937B2 (en) | HIV-1 immunogenic compositions |